{"disease":{"id":"anthracycline-refractory-tnbc","name":"anthracycline refractory tnbc"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04095689","title":"Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"The Methodist Hospital Research Institute","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}